Galapagos' Strategic Shift: Betting On CAR-T And A Fresh Start (Rating Upgrade)
Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...
Galapagos projects 2026 pivotal trials for GLPG5101 following FDA clearance
Q4 2024 Management View CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin ...
FierceBiotech7d
Galapagos drops one CD19 CAR-T to focus on 'flagship' program
Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...
Forbes1mon
Galapagos To Spin Off Innovative Medicines Business
The remaining Galapagos entity will specialize in cell therapy, focusing on its lead CAR-T candidate, GLPG5101, currently being tested for relapsed or refractory non-Hodgkin lymphoma. Additionally ...
Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience
Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...
Yahoo Finance7d
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
“With the FDA’s IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma ...
PharmiWeb7d
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
“With the FDA’s IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma indications, there is ...